BGF joins FluoRok's $30m Series A funding round
The funding supports FluoRok's transition to industrial scale and global deployment of its HF-free fluorochemical manufacturing platform.
See the latest news and media coverage for BGF. We track all announcements, press releases, and industry mentions in real time, all in one place.
Equity investment firm for growing businesses
bgf.co.ukLast updated
In short: BGF joined two funding rounds and exited Mission Mars with a 3.75x return
The funding supports FluoRok's transition to industrial scale and global deployment of its HF-free fluorochemical manufacturing platform.
The funding advances clinical development of two TCR-CD3 bispecific programmes in oncology and autoimmune disease and adds Kirsty Crame as chief development officer.
The exit delivers a 3.75x return and 21% IRR; Mission Mars grew from two venues to 44 sites employing over 1,800 people.
Its portfolio companies have created over 35,000 jobs and £8.2bn in revenue growth, with £3.7bn from more than 280 exits. BGF plans to invest a further £3bn over five years.
BGF is exploring its very first external fundraise of up to £500m to extend its investor base beyond the big four banks who founded it...
Subscribe Nearly there! A verification email is on its way to you. Please check your spam or junk folder just in case. If you do...
LONDON, Aug. 25, 2025 /PRNewswire/ -- BGF, the UK and Ireland's most active growth capital investor, today announces the successful exit of OrganOx, the Oxford-based...
LONDON, Aug. 25, 2025 /PRNewswire/ -- BGF, the UK and Ireland's most active growth capital investor, today announces the successful exit of OrganOx, the Oxford-based...
Track BGF and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to BGF and other trending companies.